Table 1.
Patient characteristics stratified by estrogen receptor status.
| Characteristic | Overall, N = 494 | ER-positive, N = 252 | ER-negative, N = 242 | p-value |
|---|---|---|---|---|
| Age 1 | 64 (52, 73) | 63 (51, 72) | 65 (53, 74) | 0.01 |
| <45 | 55 (11%) | 30 (12%) | 25 (10%) | |
| ≥45 & ≤70 | 265 (54%) | 140 (56%) | 125 (52%) | |
| >70 | 174 (35%) | 82 (33%) | 92 (38%) | |
| Disease presentation | 0.009 | |||
| Recurrent BC | 448 (91%) | 237 (94%) | 211 (87%) | |
| De novo mBC | 46 (9.3%) | 15 (6.0%) | 31 (13%) | |
| Metastatic site | ||||
| Visceral | 319 (65%) | 175 (69%) | 144 (60%) | 0.02 |
| CNS metastases | 36 (7.3%) | 16 (6.3%) | 20 (8.3%) | 0.40 |
| Number of sites | 0.02 | |||
| 1–2 | 270 (55%) | 151 (60%) | 119 (49%) | |
| ≥3 | 224 (45%) | 101 (40%) | 123 (51%) |
1
Median (IQR); n (%).
ER: estrogen receptor; BC: breast cancer; mBC: metastatic breast cancer; CNS: central nervous system.